

Human Cyclophilin A / PPIA Protein, Tag Free (MALS verified)

Catalog # CYA-H5113



Synonyms

PPIA, Cyclophilin A, Rotamase A, PPIase A, CYPA, CYPH

Source

Human Cyclophilin A Protein, Tag Free (CYA-H5113) is expressed from *E. coli* cells. It contains AA Met 1 - Glu 165 (Accession # [P62937](#)).

Predicted N-terminus: Met 1

Molecular Characterization

Cyclophilin A (Met 1 - Glu 165)

P62937

This protein carries no "tag".

The protein has a calculated MW of 18.0 kDa. The protein migrates as 15-17 kDa when calibrated against [Star Ribbon Pre-stained Protein Marker](#) under reducing (R) condition (SDS-PAGE).

Purity

>90% as determined by SDS-PAGE.

>95% as determined by SEC-MALS.

Formulation

Supplied as 0.2 µm filtered solution in PBS, pH7.4 with glycerol as protectant.

Contact us for customized product form or formulation.

Shipping and Storage

This product is supplied and shipped on dry ice.

Please avoid repeated freeze-thaw cycles.


This product is stable after storage at:

- The product MUST be stored at -70°C or lower upon receipt;
- -70°C for 3 months under sterile conditions.

ACRO Quality Management System


- [QMS\(ISO, GMP\)](#)
- [Quality Advantages](#)
- [Quality Control Process](#)

SDS-PAGE



Human Cyclophilin A Protein, Tag Free on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With [Star Ribbon Pre-stained Protein Marker](#)).

SEC-MALS



The purity of Human Cyclophilin A Protein, Tag Free (Cat. No. CYA-H5113) is more than 95% and the molecular weight of this protein is around 16-26 kDa verified by SEC-MALS.

Background

Cyclophilin A (CypA) is a highly abundant intracellular peptidyl-prolyl isomerase. Traditionally targeted by immunosuppressants and antivirals, CypA is now driving a paradigm shift in oncology. In novel "tri-complex" therapies, small molecules bind CypA, leveraging its bulky protein structure to form a neo-interface. This complex acts as a steric shield to effectively lock and inhibit previously "undruggable" targets like active KRAS.



www.acrobiosystems.com